AbbVie, Thermo Fisher Scientific, Vertex Pharmaceuticals, Danaher, and Cognizant Technology Solutions are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business involves researching, developing, and commercializing products based on biological processes—such as drugs, diagnostics, or agricultural technologies. Because these firms often invest heavily in early‐stage research and face lengthy regulatory approval processes, their stock prices can be more volatile, offering both high growth potential and elevated risk. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of ABBV traded up $5.28 during midday trading on Friday, reaching $198.62. The stock had a trading volume of 6,424,665 shares, compared to its average volume of 6,081,067. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The company's fifty day simple moving average is $196.14 and its two-hundred day simple moving average is $187.25. The company has a market cap of $351.35 billion, a price-to-earnings ratio of 82.76, a PEG ratio of 1.62 and a beta of 0.56. AbbVie has a 1-year low of $153.58 and a 1-year high of $218.66.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded up $3.80 on Friday, hitting $423.69. 2,492,422 shares of the company's stock were exchanged, compared to its average volume of 1,769,243. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific has a 1-year low of $409.85 and a 1-year high of $627.88. The company has a market capitalization of $159.94 billion, a PE ratio of 25.63, a P/E/G ratio of 2.99 and a beta of 0.86. The firm's 50-day moving average is $476.15 and its 200 day moving average is $521.64.
Read Our Latest Research Report on TMO
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Vertex Pharmaceuticals stock traded up $2.29 during mid-day trading on Friday, hitting $501.15. The company had a trading volume of 1,652,430 shares, compared to its average volume of 1,342,700. The stock has a market cap of $128.84 billion, a price-to-earnings ratio of -227.80, a PEG ratio of 2.11 and a beta of 0.50. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The business has a fifty day moving average of $492.00 and a 200 day moving average of $467.15.
Read Our Latest Research Report on VRTX
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
DHR traded up $2.44 on Friday, reaching $199.15. The company had a trading volume of 3,159,138 shares, compared to its average volume of 3,367,010. The stock has a market capitalization of $142.53 billion, a PE ratio of 37.72, a P/E/G ratio of 2.66 and a beta of 0.80. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70. The stock has a 50-day moving average price of $199.78 and a 200-day moving average price of $222.10.
Read Our Latest Research Report on DHR
Cognizant Technology Solutions (CTSH)
Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. It operates through four segments: Financial Services, Health Sciences, Products and Resources, and Communications, Media and Technology.
Shares of Cognizant Technology Solutions stock traded up $2.47 during trading on Friday, reaching $77.70. The company's stock had a trading volume of 5,330,479 shares, compared to its average volume of 3,596,424. The company has a 50-day moving average price of $75.76 and a two-hundred day moving average price of $78.56. Cognizant Technology Solutions has a fifty-two week low of $63.79 and a fifty-two week high of $90.82. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. The firm has a market cap of $38.43 billion, a PE ratio of 17.23, a P/E/G ratio of 2.11 and a beta of 1.03.
Read Our Latest Research Report on CTSH
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
